Ivermectin therapy for young children with scabies infection: a multicentre phase 2 non-randomized trialResearch in context

• Main Authors: Amanda Gwee (Author), Andrew Steer (Author), Khampheng Phongluxa (Author), Chanthaly Luangphaxay (Author), Khanpaseuth Senggnam (Author), Ammala Philavanh (Author), Alice Lei (Author), April Martinez (Author), Shan Huang (Author), Brett McWhinney (Author), Jacobus Ungerer (Author), Stephen Duffull (Author), Wenyu Yang (Author), Xiao Zhu (Author), Ben Coghlan (Author)
• Format: Book
• Published: Elsevier, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: Ivermectin, an effective treatment for scabies, is not licensed for children weighing <15 kg. Pharmacokinetic modelling has shown a 3 mg dose in young children (2-4 years, weighing 10-14 kg) achieves comparable drug exposure to a 200 μg/kg dose in children aged ≥5 years. This...